Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of Oral TAK-715 in the Treatment of the Signs and Symptoms of Rheumatoid Arthritis.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs TAK 715 (Primary) ; Methotrexate
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Takeda Global Research and Development Center
- 06 Nov 2012 Planned number of patients (400) added as reported by European Clinical Trials Database record.
- 15 Oct 2008 New trial record.